Mediar Therapeutics
PrivateLast Round
Series B
Jan 7, 2026
Est. Valuation
$230.3M
Total Funding Raised
$181M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Mediar Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2026.
Mediar Therapeutics is a biotechnology company developing innovative antibody-based therapies aimed at halting and reversing fibrotic activity in chronic organ damage.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mediar Therapeutics Comparables
Compare Mediar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Endeavor BioMedicines | 81% | |
| Certa Therapeutics | 81% | |
| AgomAb Therapeutics | 80% |
For institutional investors. Book with your work email.
Mediar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 7, 2026 | ||||
| Series A | Mar 15, 2023 | ||||
| Seed | Mar 17, 2021 |
For institutional investors. Book with your work email.
Mediar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Seed |
| Gimv | Series B, Series A |
| Asahi Kasei Pharma Ventures | Series B |
| Amplitude Ventures | Series B |
| Mass General Brigham Innovation | Series A, Seed |
| Intermediate Capital Group | Series B |
| Viva Biotech | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 108% MoM, reaching 4.3K.
- Jan 7, 2026
$76M round completed.
For institutional investors. Book with your work email.
Mediar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mediar Therapeutics's valuation, stock price, and market status.
Is Mediar Therapeutics a public or private company?
Mediar Therapeutics is a private company.
What is the current stock price of Mediar Therapeutics?
Mediar Therapeutics is a private company, so its shares have no public market price. Caplight tracks Mediar Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mediar Therapeutics worth (valuation)?
Mediar Therapeutics's valuation is estimated at $230.3M based on funding round data.
Can I buy Mediar Therapeutics stock?
Mediar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mediar Therapeutics's last funding round?
Mediar Therapeutics's most recent funding round was Series B on January 7, 2026.
Who are the main investors in Mediar Therapeutics?
Key investors in Mediar Therapeutics include Sofinnova Partners.
Will Mediar Therapeutics IPO soon?
No public IPO plans have been announced for Mediar Therapeutics.
How can I track Mediar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Mediar Therapeutics's shares on secondary markets.